Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06125717 | Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP | PHASE1 | COMPLETED | 45 | — | — | Jul 2, 2022 | Mar 13, 2023 | Nov 9, 2023 | 3 | Canada |
| Arm | Type | Description |
|---|---|---|
| 15 μg of the H1 influenza antigen | ACTIVE_COMPARATOR | - |
| 7.5 μg of the H1 influenza antigen | ACTIVE_COMPARATOR | - |
| Placebo (no antigen) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| H1 influenza antigen | BIOLOGICAL | Either 7.5 μg or 15 μg of the H1 influenza antigen |
Inclusion Criteria: * Male or female aged 18 - 39 years inclusive * Provide written informed consent to participate * Healthy participants without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality o As determined by medical history, physi...